stockrow
Saturday 7 November 2026
Export SGP’s income statement to Excel — free account
SpyGlass Pharma, Inc.
36.42
2.34
+6.87%
Follow SGP
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+5 more quarters Free account |
18.11 | 12.67 | 38.00 | 25.06 |
Net Debt/EBITDA |
0.00 | 0.00 | 16.63 | 10.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.98 | 0.75 | |
Capex/Depreciation |
(1.11) | — | (2.13) | (5.65) | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (0.50) | |
Cash per Share |
0.00 | 0.00 | 0.01 | 7.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.01 | 6.95 | |
Interest Debt per Share |
— | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.01 | 6.95 | |
Free Cash Flow |
(8.99) | — | (14.22) | (16.77) | |
Working Capital |
113.09 | 100.18 | 246.70 | 227.02 | |
Capital Expenditures |
(0.15) | — | (0.68) | (1.93) | |
Net Current Asset Value |
(94.54) | (105.93) | 245.09 | 225.39 | |
| Other line items | |||||
Quick Ratio |
17.92 | 12.57 | 37.75 | 24.89 | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | (0.44) | |
Capex per Share |
0.00 | — | 0.00 | (0.06) | |
Average Receivables |
— | — | — | 0.40 | |
Average Payables |
— | — | — | 2.40 | |
Average Assets |
63.51 | 57.93 | 129.19 | 142.29 | |
Average Common Equity |
— | — | — | 99.69 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026